a8235ad1-0c5f-4a0b-b595-85ef3a1e49ff
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 78.4147843942505
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.530
- HEDGEHOG_SIGNALING+0.440
- WNT_BETA_CATENIN_SIGNALING+0.420
- APICAL_SURFACE+0.340
- APICAL_JUNCTION+0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.310
- ESTROGEN_RESPONSE_EARLY+0.290
- MYOGENESIS+0.270
- MYC_TARGETS_V2+0.240
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.220
Top 10 suppressed
- PROTEIN_SECRETION-0.490
- ANDROGEN_RESPONSE-0.350
- E2F_TARGETS-0.290
- INTERFERON_ALPHA_RESPONSE-0.290
- INTERFERON_GAMMA_RESPONSE-0.250
- ALLOGRAFT_REJECTION-0.240
- MYC_TARGETS_V1-0.240
- G2M_CHECKPOINT-0.200
- UV_RESPONSE_DN-0.190
- SPERMATOGENESIS-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a4322796-9189-48c2-9e7c-7b1493b5799a | — | — | 0.931 |
| 2 | 1c3d6580-0dc8-4346-a4f7-0bb404d4a245 | — | — | 0.891 |
| 3 | 290b89f5-2a44-424b-b77d-a190dcb93e07 | — | — | 0.888 |
| 4 | c0054cf0-8f4b-47b6-a8fc-63a1fd36bcc7 | — | — | 0.872 |
| 5 | 1e82995c-f318-4225-96d4-f1e98bcbf60b | — | — | 0.860 |
| 6 | 40b92a76-f324-4cdd-8209-517d021acd47 | — | — | 0.855 |
| 7 | 80bea63b-bc3a-4999-8c11-a35c92183cd7 | — | — | 0.851 |
| 8 | MNG545 | — | — | 0.847 |
| 9 | MDT-AP-1336 | Med | Medulloblastoma | 0.825 |
| 10 | 05167d53-0b47-4131-bfa4-450b236b9fd5 | — | — | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.530 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.440 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.420 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.340 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.290 | Inavolisib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.220 | Idelalisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| HYPOXIA | 0.110 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |